- FDA Approves a Biosimilar to Bevacizumab
- ESMO 2017: Adjuvant Dabrafenib Plus Trametinib Significantly Lowers Risk of Death in Stage III BRAF V600–Mutated Melanoma
- ESMO 2017: BRIM8 Data Shows Benefit with Adjuvant Vemurafenib in Resected BRAFV600 Positive Melanoma
- ESMO 2017: First-line Dabrafenib and Trametinib Shows Substantial Clinical Activity in BRAF V600E–mutated Metastatic NSCLC
- ESMO 2017: Ramucirumab Improves PFS in Patients with Platinum Refractory Advanced Urothelial Carcinoma
- ESMO 2017: Nivolumab Plus Ipilimumab versus Sunitinib in First-Line Treatment for Advanced or Metastatic RCC
- ESMO 2017: Combined Abemaciclib with NSAI Show Significant Clinical Benefit as Initial Treatment for Patients with HR-positive/HER2-negative ABC at Interim Analysis
- ESMO 2017: Biosimilar Rituximab Shows Equivalent Efficacy to Reference Rituximab in Previously Untreated Advanced Follicular Lymphoma
- ESMO 2017: Front-Line Osimertinib Poised to Become Standard of Care in EGFR-Mutation Positive NSCLC
- ESMO 2017: Adjuvant Imatinib Recommended Only for Patients with High-risk GIST
- ESMO 2017: Promising Results Demonstrated with DCC-2618 in GIST
- ESMO 2017: Overall Survival Benefit is Seen with Olaparib in Patients with Ovarian Cancer and TP53 Disruptive Mutation Status
- ESMO 2017: Progression-free Rate Unaffected by Sequence of Cytoreductive Nephrectomy and Sunitinib in Patients with Synchronous mRCC
- ESMO 2017: Rucaparib Shows Clinical Benefit as Maintenance Therapy in Patients with Recurrent Ovarian Cancer
- ESMO 2017: Patients with Platinum Sensitive Ovarian Cancer Maintan QoL During Maintenance Niraparib Therapy
- ESMO 2017: Adding Abiraterone Acetate or Docetaxel Plus Prednisone to Standard of Care in Patients with High-Risk Prostate Cancer
- ESMO 2017: Combined Taselisib and Letrozole Improves Response in Postmenopausal Women with ER-positive, HER-negative Early Breast Cancer
- ESMO 2017: Invasive DFS Rates Following Trastuzumab are Improved with Neratinib Over Placebo in Early Stage HER2-positive Breast Cancer
- ESMO 2017: Pembrolizumab Demonstrates Antitumour Activity in Advanced Gastric Cancer as Monotherapy and Combined with Chemotherapy
- ESMO 2017: Combined Letrozole plus Palbociclib is not Better than Chemotherapy as Neoadjuvant Treatment in Luminal Breast Cancer
- FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML
- Ribociclib Receives EU Approval as First-Line Treatment for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
- NICE Issues Technology Appraisal Guidance on Olaratumab in Combination with Doxorubicin for Treating Advanced STS
- FDA Approves Inotuzumab Ozogamicin for Relapsed or Refractory B-Cell Precursor ALL
- FDA Expands Ibrutinib Indications to Chronic GVHD